Search Results
Showing 10 of 18,975 search results for:
Hydroxychloroquine for Treatment of Non-Severe COVID-19
Status
Condition
Covid19
Phase
INTERVENTION
Drug: Hydroxychloroquine tablets
Eligibility
Ages Eligible for Study : 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 1 of 10
Proxalutamide Treatment for COVID-19 Female Outpatients
Status
Condition
SARS-CoV Infection, Covid19
Phase
INTERVENTION
Drug: Proxalutamide, Other: Standard of Care
Eligibility
Ages Eligible for Study : 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study : Female
Accepts Healthy Volunteers : No
Result 2 of 10
A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
Status
Condition
Chronic Hepatitis B
Phase
INTERVENTION
Drug: Peginterferon alfa-2b injection, Drug: Peginterferon alfa-2b injection, Drug: TDF, Drug: Peginterferon alfa-2b injection
Eligibility
Ages Eligible for Study : 18 to 65 Years (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 3 of 10
Immunocompromised Swiss Cohorts Based Trial Platform
Status
Condition
Immunocompromised Patients
Phase
INTERVENTION
Biological: Moderna COVID-19 Vaccine, mRNA-1273 (100 μg), Biological: Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)
Eligibility
Ages Eligible for Study : 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 4 of 10
A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
Status
Condition
Psoriasis
Phase
INTERVENTION
Biological: CT-P43, Biological: Stelara
Eligibility
Ages Eligible for Study : 18 to 80 Years (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 5 of 10
A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects
Status
Condition
Healthy
Phase
INTERVENTION
Drug: Tralokinumab administered as 1 × X mL with Device A, Device: Tralokinumab administered as 2 × Y mL with Device B
Eligibility
Ages Eligible for Study : 18 to 55 Years (Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : Yes
Result 6 of 10
A Study of PRA023 in Healthy Volunteers
Status
Condition
Healthy
Phase
INTERVENTION
Drug: PRA023, Other: Placebo
Eligibility
Ages Eligible for Study : 18 to 55 Years (Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : Yes
Result 7 of 10
A Study of the Cardiac Effects of ALXN2050 in Healthy Adults
Status
Condition
Healthy
Phase
INTERVENTION
Drug: ALXN2050, Drug: ALXN2050-matching Placebo, Drug: Moxifloxacin, Drug: Moxifloxacin-matching Placebo
Eligibility
Ages Eligible for Study : 18 to 55 Years (Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : Yes
Result 8 of 10
Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial
Status
Condition
Venous Thromboembolism, Covid19
Phase
INTERVENTION
Drug: Rivaroxaban 10 MG
Eligibility
Ages Eligible for Study : 18 to 90 Years (Adult, Older Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 9 of 10
Clinical Study of Platelet-rich Plasma Promoting Tendon-bone Healing in Anterior Cruciate Ligament Reconstruction
Status
Condition
Sports Injury
Phase
INTERVENTION
Drug: Platelet-Rich Plasma
Eligibility
Ages Eligible for Study : 15 to 50 Years (Child, Adult)
Sexes Eligible for Study : All
Accepts Healthy Volunteers : No
Result 10 of 10